Ispectamab debotansine
- Generic Name
- Ispectamab debotansine
- Drug Type
- Biotech
- CAS Number
- 2413386-21-5
- Unique Ingredient Identifier
- WY39ZX6NZU
- Background
Ispectamab debotansine is an antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 humanized antibody conjugated covalently to the dibenzocyclooctyne (DBCO) noncleavable linker maytansinoid warhead.
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 160
- Registration Number
- NCT04036461
- Locations
- 🇺🇸
Local Institution - 102, Seattle, Washington, United States
🇺🇸Local Institution - 104, Dallas, Texas, United States
🇨🇦Local Institution - 202, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath